Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?

Neurology. 2003 Apr 22;60(8):1374-7. doi: 10.1212/01.wnl.0000055847.17752.e6.

Abstract

Patients with mild cognitive impairment (MCI) were assessed, and a metabolic profile associated with conversion to AD at 18-month follow-up was sought. As compared with nonconverters (n = 10), converters (n = 7) had lower fluorodeoxyglucose uptake in the right temporoparietal cortex (p = 0.02, corrected for cluster size), without individual overlap. Awaiting replication in an independent sample, these findings suggest that among patients with MCI, fluorodeoxyglucose PET may accurately identify rapid converters.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / diagnostic imaging*
  • Alzheimer Disease / epidemiology
  • Brain / diagnostic imaging
  • Disease Progression
  • Female
  • Fluorodeoxyglucose F18
  • Gyrus Cinguli / diagnostic imaging
  • Humans
  • Male
  • Memory Disorders / diagnostic imaging
  • Middle Aged
  • Neuropsychological Tests
  • Parietal Lobe / diagnostic imaging
  • Prospective Studies
  • Radiopharmaceuticals
  • Risk Factors
  • Single-Blind Method
  • Temporal Lobe / diagnostic imaging
  • Tomography, Emission-Computed*

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18